On Tuesday, CSL Limited (ASX: CSL) announced its decision to acquire 80% of the equity of plasma-derived therapies manufacturer, Wuhan Zhong Yuan Rui De Biological Products (Ruide) in China for US $352 million. The transaction will see the company enter the Chinese domestic plasma fractionation market. CSL Limited has demonstrated significant earnings momentum in FY17, and we see this continuing into the new financial year. Shares in CSL Limited closed up 2.9% for the week. We own CSL Limited as a market-driven investment in WAM Leaders.
Please sign in to comment on this wire.